ANIP(ANI Pharmaceuticals, Inc.) 的财务报表:医疗保健,特药与仿制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $216.14M | $316.38M | $486.82M | $614.38M | $883.37M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | −$39.79M | −$35.28M | $46.97M | $584.00K | $111.09M |
| 净利润 | −$42.60M | −$47.90M | $18.78M | −$18.52M | $78.34M |
| 经营现金流 | $3.32M | −$31.20M | $118.96M | $64.02M | $185.22M |
| 自由现金流 | $765.00K | −$40.08M | $110.09M | $47.78M | $171.39M |
| 摊薄每股收益 | $-3.40 | $-3.05 | $0.85 | $-1.04 | $3.32 |